Inhibrx Biosciences, Inc. is a biopharmaceutical company currently in its clinical development phase, focused on creating and advancing biological treatments for patients afflicted with severe, life-threatening medical conditions. Its pipeline features several investigational therapies, notably INBRX-109. This tetravalent therapeutic candidate, which targets death-receptor 5, is undergoing Phase 2 clinical trials for managing conventional chondrosarcoma that is either unresectable or has spread. Another significant asset is INBRX-106, a hexavalent sdAb-based candidate engineered to engage OX4, also in Phase 2 clinical evaluation. This drug aims to treat a broad spectrum of advanced cancers, including metastatic solid tumors, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA), renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was established in 2024 and is headquartered in La Jolla, California.
